Topical retinol does not affect hair loss and may help hair regrowth. It is different from isotretinoin, which can cause hair loss due to its systemic effects.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
A dermatologist advised stopping minoxidil and trying redensyl serum, while also starting finasteride. Concerns were raised about increased hair loss after stopping minoxidil.
People discussed treatments for hair thinning on the sides, mentioning Finasteride, Dutasteride, Pyrilutamide, and RU58841. One person is currently using Finasteride and seeking advice on its effectiveness for this issue.
The user is allergic to minoxidil and experienced severe itching and redness. They are considering alternatives like finasteride, dutasteride, and dermarolling for hair loss treatment.
Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.
The user experienced worsening hair loss despite using oral minoxidil, finasteride, and topical minoxidil for nine months. They are considering switching to dutasteride and reducing ketoconazole shampoo due to its drying effects.
The user changed their hair loss treatment in October/November, experienced increased shedding, and now sees no new hair growth, with a worsening condition and a possible bald spot. They also have severe seborrheic dermatitis, which may be affecting their scalp and hair loss.
Adding RU58841 to Dutasteride treatment helped reduce hair shedding significantly for several users. Some reported no change with RU58841, while others experienced a dramatic decrease in shedding and increased hair density.
The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
A user experienced significant hair loss after starting microneedling, despite using dutasteride and topical minoxidil. They are advised to consult a doctor as the shedding pattern is unusual and may indicate alopecia areata or other scalp conditions.
Alfatradiol is considered a mild treatment for hair loss, often used alongside other treatments like finasteride, minoxidil, and dutasteride. Users report it helps maintain hair but is not effective for regrowth on its own.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
The user is experiencing diffuse hair thinning despite using dutasteride and minoxidil for over five years and is considering adding oral minoxidil, microneedling, and nizoral to their regimen. They are concerned about the effectiveness and side effects of these treatments, especially with an upcoming event.
The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
The conversation is about alternative measures for hair regrowth for those who did not respond to finasteride or dutasteride, including the use of minoxidil and addressing vitamin deficiencies through blood tests.
OP is pausing hair loss treatments to focus on mental health due to anxiety and side effects from RU58841. They plan to try topical finasteride and minoxidil after recovering from pneumonia.
The user is experiencing hair regrowth after 4.5 months of using oral minoxidil, oral dutasteride, latanoprost, ketoconazole shampoo, and dermarolling. They report shedding initially but have seen improvement without significant side effects.
The user experienced side effects like heart palpitations, chest tightness, and fatigue from using 5% minoxidil foam once daily. They are considering switching to a 2% concentration due to lingering symptoms like lightheadedness and brain fog.
Prolonged use of topical minoxidil and finasteride can lead to neuroendocrine and autonomic dysfunction, causing severe sensitivity and side effects. Recovery involves avoiding these treatments, supporting neurosteroid recovery, calming the sympathetic system, and rebuilding scalp health naturally.
The user is on their 5th week of using pyrilutamide for hair loss without experiencing side effects and has noticed slight hair growth. They also use minoxidil with finasteride and dutasteride as part of their treatment regimen.
Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.
Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.